Navigation Links
OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer
Date:6/24/2009

vival as the primary endpoint in patients treated with first-line docetaxel chemotherapy; the other trial design investigates pain palliation as the primary endpoint in patients treated with second-line docetaxel chemotherapy.

OGX-011 has received Fast Track designation from the FDA for the treatment of progressive metastatic prostate cancer in combination with docetaxel.

About the Special Protocol Assessment and Agreement Process

Under a Special Protocol Assessment (SPA), a company and the FDA can reach an agreement on the design and size of a clinical trial to support a regulatory submission. This agreement can be in writing and cannot be changed after the clinical trial begins except: (i) with written agreement of the company and the FDA; or (ii) if the director of the FDA reviewing division determines that "a substantial scientific issue essential to determining the safety or effectiveness of the drug" was identified after testing began.

About OncoGenex

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new therapies that address unmet needs in the treatment of cancer. OncoGenex has a deep oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OGX-011, the lead candidate that has completed five Phase 2 clinical trials in prostate, lung and breast cancers, is designed to inhibit the production of a specific protein associated with treatment resistance; OGX-427 is in Phase 1 clinical development; SN2310 has completed the Phase 1 clinical trial; and CSP-9222 and OGX-225 are currently in pre-clinical development.

OGX-011, OGX-427 and OGX-225 utilize second-generation antisense technology, licensed from Isis Pharmaceuticals (NASDAQ: ISIS), to effective
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer
2. OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial
3. OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009
4. OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427
5. OncoGenex Pharmaceuticals Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting
6. OncoGenex Reports First Quarter Financial Results
7. OncoGenex Pharmaceuticals to Release First Quarter Financial Results
8. OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer
9. OncoGenex Pharmaceuticals Named Life Sciences Company of the Year by LifeSciences British Columbia
10. OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
11. OncoGenex Pharmaceuticals to Webcast Financial Results for Fourth Quarter and Fiscal Year 2008 and Provide Outlook for 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 20, 2014 Not long ago, it ... should be performed late in the development cycle – ... current regulatory trends suggest that, like many things GxP, ... In recent years, multiple drug sponsors have been required ... specific questions during phase I/II. It’s not only clinical ...
(Date:8/20/2014)... WriteResult®, a leading provider of Electronic Patient Outcome ... myPROpad™ ePRO tablet with the addition of a touchscreen ... widely used and well-respected Patient Reported Outcome (PRO) instruments ... used during clinical trials and in other health care ... to demonstrate Health-Related Quality of Life outcomes (HRQoL) resulting ...
(Date:8/19/2014)... Shimadzu Scientific Instruments has introduced ... Nexera-i, adding to the company’s extensive line-up of ... intuitive operating environment, and full automation, the i-Series ... for conventional to ultra-high-speed analysis. , ... design so users can begin building the lab ...
(Date:8/19/2014)... Calif. (PRWEB) August 19, 2014 ... campaign to raise $200,000 to fund a corporate ... device. , This development is a critical ... model of care to the implementation of personalized ... method of practicing medicine. , Indiegogo contributions will ...
Breaking Biology Technology:Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2EQ-5D™ Assessment Now Available for iPad 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 2Shimadzu’s New i-Series Integrated Liquid Chromatography Systems Provide Laboratories Wider Range of Analytical Capabilities 3Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3
... BIRMINGHAM, Ala., Oct. 31 BioCryst,Pharmaceuticals, Inc. (Nasdaq: ... quarter ended September 30, 2008., Third Quarter ... ended September 30, 2008, the Company reported,collaborative and ... to $20.5 million for the three months ended ...
... and waves erode billions of tons of soil from ... plagued with excessive amounts of suspended sediment. According to ... the largest nonpoint source pollution in the environment. , ... obvious wind, water and wave forces breaking apart particles ...
... 30 AVAX Technologies, Inc.,(OTC Bulletin Board: AVXT) ... it closed a bridge loan financing pursuant to ... by the Amendment to Convertible,Note and Warrant Purchase ... Company sold convertible promissory notes,(the "Notes") in the ...
Cached Biology Technology:BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 2BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 3BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 4BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 5BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 6BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 7BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 8BioCryst Reports Third Quarter 2008 Financial Results and Provides Corporate Update 9Virginia Tech engineers identify conditions that initiate erosion 2Virginia Tech engineers identify conditions that initiate erosion 3AVAX Technologies, Inc. Announces Closing of Bridge Loan Financing 2
(Date:8/21/2014)... , Aug. 21, 2014 Nxt-ID, Inc. (OTCQB: ... mobile commerce market, announced today that its shares of ... to be issued in its proposed underwritten public offering ... listing on The Nasdaq Capital Market, subject to closing ... stock and warrants, and will trade under the symbol ...
(Date:8/21/2014)... might seem easy to ignore, but they are the ... depend upon. Humans are increasingly dependent on algae, too, ... and sink it to the bottom of the ocean. ... laboratory experiments, researchers have evidence showing that viruses infecting ... algae,s blooms, even when all else stays essentially the ...
(Date:8/21/2014)... 2014 /PRNewswire-iReach/ -- LiveScan Service Provider  Binary ... a partnership with Gabriel Health Institute, one of ... Certified Nursing Assistant preparatory schools. The agreement ... member of Binary,s LiveScan service provider,s owner/operator team; ... its service capabilities by widening the service ...
Breaking Biology News(10 mins):Nxt-ID Approved for NASDAQ Capital Market Listing 2Nxt-ID Approved for NASDAQ Capital Market Listing 3Viruses take down massive algal blooms, with big implications for climate 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 2LiveScan Provider Binary Biometrics Announces Partnership with Preeminent CNA School, Gabriel Health Institute to Expand Services in Orlando Region 3
... comet-like tail Mercurys gravity is too weak ... evaporated from the surface by solar photons or other ... escape velocity by solar radiation pressure. The neutral components ... points away from the Sun. Baumgardner et al. study ...
... of a massive online Encyclopedia of Life (EOL) were ... Entertainment and Design (TED) Conference in Monterey, California. ... and a fascinating resource for anyone interested in the ... unique collaboration between scientists and the general public. ...
... the significance of taste to both human gratification and survival, ... Taste provides both pleasure and protection. Often taken ... into their mouths. Taste mediates recognition of a substance and ... taken into the body, or rejected as inappropriate. ...
Cached Biology News:AGU journal highlights -- Feb. 26, 2008 2AGU journal highlights -- Feb. 26, 2008 3AGU journal highlights -- Feb. 26, 2008 4AGU journal highlights -- Feb. 26, 2008 5AGU journal highlights -- Feb. 26, 2008 6MBL develops infrastructure and portal for Encyclopedia of Life 2MBL develops infrastructure and portal for Encyclopedia of Life 3MBL develops infrastructure and portal for Encyclopedia of Life 4MBL develops infrastructure and portal for Encyclopedia of Life 5From delicious to death: Understanding taste 2
... QPlate is the consumable measurement ... contains 16 individually controlled measurement ... a sophisticated liquid flow channel ... and precise solution and compound ...
... software, a multitasking application capable of dynamic ... and operation of lab automation workcells easy ... custom modification by programmers. • ... drag-anddrop flowchart. If you can build a ...
... As research demands continue to grow, the ... spectral information has become necessary, especially when ... colors. The innovative C1si Confocal Microscope System ... and spectral capability not available in conventional ...
... assay kit provides complete components including ... convenient detection of DNA fragmentation in ... incorporation of BrdU in the procedure ... digoxigenylated methods. Results can be analyzed ...
Biology Products: